MAP3K14 and Hodgkins lymphoma: For example, NIK and the noncanonical NF-κB pathway was shown to be stably activated in Hodgkin lymphoma (HL) cell lines and tumors, and treatment with a NIK small molecule inhibitor, 4H-isoquinoline-1,3-dione, significantly reduced HL cell viability [53].